<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00445588</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-03018</org_study_id>
    <secondary_id>NCI-2012-03018</secondary_id>
    <secondary_id>CDR531731</secondary_id>
    <secondary_id>NABTT 0502</secondary_id>
    <secondary_id>NABTT-0502</secondary_id>
    <secondary_id>U01CA062475</secondary_id>
    <nct_id>NCT00445588</nct_id>
  </id_info>
  <brief_title>Erlotinib and Sorafenib in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme</brief_title>
  <official_title>A Phase II Trial of Erlotinib (OSI-774) and Sorafenib (BAY 43-9006) for Patients With Progression or Recurrent Glioblastoma Multiforme</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial is studying how well giving erlotinib together with sorafenib works in&#xD;
      treating patients with progressive or recurrent glioblastoma multiforme. Erlotinib and&#xD;
      sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell&#xD;
      growth and by blocking blood flow to the tumor. Giving erlotinib together with sorafenib may&#xD;
      kill more tumor cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. The primary objective of this trial is to estimate the overall survival rate associated&#xD;
      with this combined regimen in treating adult patients with recurrent glioblastoma multiforme.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To assess and estimate the toxicities. II. Tumor response rate. III. To estimate 6-month&#xD;
      progression free survival. IV. To describe the pharmacokinetics of this route of&#xD;
      administration. V. For the Molecular Targeted Combinations Correlative (MTC2) Study&#xD;
      Initiative: To determine the relationship between tumor and blood biomarkers and clinical&#xD;
      outcome of patients treated with the combination of targeted agents.&#xD;
&#xD;
      OUTLINE: This is a multicenter, open-label, phase II study.&#xD;
&#xD;
      Patients receive oral erlotinib hydrochloride once daily and oral sorafenib tosylate twice&#xD;
      daily on days 1-28. Treatment repeats every 4 weeks in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      Tumor tissue and blood samples are collected prior to beginning treatment. Samples are&#xD;
      analyzed by immunohistochemistry, gene expression, and DNA mutation and genomic analyses of&#xD;
      the epidermal growth factor receptor, ras-raf-ERK, and PI3K-Akt-mTOR pathways to identify&#xD;
      markers that correlate with patient outcomes. Blood samples are also collected on day 15 of&#xD;
      course 1 for pharmacokinetic studies. Samples are analyzed by reversed-phase isocratic&#xD;
      high-performance liquid chromatography with electrospray ionization mass spectrometry to&#xD;
      determine the concentration of erlotinib hydrochloride and sorafenib tosylate and its known&#xD;
      metabolites.&#xD;
&#xD;
      After completion of study therapy, patients are followed every 2 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Time of first day of the treatment to death, assessed up to 2 years</time_frame>
    <description>death. measured by time of first day of treatment until date of death, assessed up to 2 years.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>6months -Progression-free Survival Rate</measure>
    <time_frame>At 6 months- defined as patient started treatment is alive and progression free at the time of 26-week (6 months) follow-up</time_frame>
    <description>defined patient started treatment is alive and progression free at the time of 26-week (6 months) follow-up</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Adult Giant Cell Glioblastoma</condition>
  <condition>Adult Glioblastoma</condition>
  <condition>Adult Gliosarcoma</condition>
  <condition>Recurrent Adult Brain Tumor</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral erlotinib hydrochloride 150mg once daily and oral sorafenib tosylate 400mg twice daily on days 1-28. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.&#xD;
Other: pharmacological study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib hydrochloride</intervention_name>
    <description>150mg Given orally once daily</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>OSI-774</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sorafenib tosylate</intervention_name>
    <description>400mg Given orally twice daily</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>BAY 3-9006</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have histologically confirmed supratentorial glioblastoma multiforme&#xD;
             which is progressive or recurrent after radiation therapy ± chemotherapy; patients&#xD;
             with previous low grade glioma who progressed after radiotherapy ± chemotherapy and&#xD;
             are biopsied and found to have a high grade glioma are eligible&#xD;
&#xD;
          -  Patients must have tissue specimens available and agree to have their blood and tissue&#xD;
             blocks (or slides) submitted for the combined correlative studies&#xD;
&#xD;
          -  Patients must have measurable contrast enhancing progressive or recurrent glioblastoma&#xD;
             multiforme by MRI or CT imaging (Within 14 days before starting treatment)&#xD;
&#xD;
          -  Patients must have recovered from toxicity of prior therapy. An interval of at least 3&#xD;
             months must have elapsed since the completion of the most recent course of radiation&#xD;
             therapy, while at least 3 weeks must have elapsed since the completion of a&#xD;
             non-nitrosourea containing chemotherapy regimen, and at least 6 weeks since the&#xD;
             completion of a nitrosourea containing chemotherapy regimen; NOTE: For a&#xD;
             non-cytotoxic, FDA approved agents (i.e. Celebrex, thalidomide, etc.) therapy could be&#xD;
             started 2 weeks after discontinuing this agent provided the patient has fully&#xD;
             recovered from all toxicity associated with the agent; for investigational,&#xD;
             non-cytotoxic agents a minimum of 3 weeks must have elapsed before the patient will be&#xD;
             eligible for this study&#xD;
&#xD;
          -  Patients must have a Karnofsky performance status &gt;= 60% (i.e. the patient must be&#xD;
             able to care for himself/herself with occasional help from others)&#xD;
&#xD;
          -  Absolute Neutrophil Count &gt;= 1500/mm^3&#xD;
&#xD;
          -  Platelets &gt;= 100,000/mm^3&#xD;
&#xD;
          -  Creatinine =&lt; 1.7mg/dl&#xD;
&#xD;
          -  Total Bilirubin within normal institutional limits&#xD;
&#xD;
          -  Transaminases =&lt; 2.5 times above the upper limits of the institutional norm&#xD;
&#xD;
          -  PT, PTT ≤ institutional norm&#xD;
&#xD;
          -  Patients must be able to provide written informed consent&#xD;
&#xD;
          -  Patients with the potential for pregnancy or impregnating their partner must agree to&#xD;
             follow acceptable birth control methods to avoid conception; women of childbearing&#xD;
             potential must have a negative serum pregnancy test; (the anti-proliferative activity&#xD;
             of this experimental drug may be harmful to the developing fetus or nursing infant)&#xD;
&#xD;
          -  Patients must have a Mini Mental State Exam score &gt;= 15&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with serious concurrent infection or medical illness which would jeopardize&#xD;
             the ability of the patient to receive the treatment outlined in this protocol with&#xD;
             reasonable safety; (examples of medical illnesses are [but not limited to] the&#xD;
             following: uncontrolled hypertension, symptomatic congestive heart failure, unstable&#xD;
             angina pectoris, cardiac arrhythmia, or psychiatric illness/social situation that&#xD;
             would limit compliance with study requirements)&#xD;
&#xD;
          -  Patients with uncontrolled hypertension; hypertension with systolic blood pressure of&#xD;
             &gt; 140 mmHg or diastolic pressure &gt; 90 mmHg; however, patients with well-controlled&#xD;
             hypertension are eligible&#xD;
&#xD;
          -  Patients who are pregnant or breast-feeding (the anti-proliferative activity of this&#xD;
             experimental drug may be harmful to the developing fetus or nursing infant)&#xD;
&#xD;
          -  Patients who have received more than two prior treatments&#xD;
&#xD;
          -  Patients who have had prior therapy with erlotinib or sorafenib or any other agent&#xD;
             targeting EGFR&#xD;
&#xD;
          -  Patients receiving concurrent therapy for their tumor (with the exception of steroids)&#xD;
&#xD;
          -  Patients undergoing major surgery or sustaining a significant traumatic injury within&#xD;
             21 days prior to treatment are ineligible&#xD;
&#xD;
          -  Patients with a concurrent malignancy are ineligible unless they are patients with&#xD;
             curatively treated carcinoma-in-situ or basal cell carcinoma of the skin; patients&#xD;
             with a prior malignancy are ineligible unless they have been free of disease for &gt;=&#xD;
             five years&#xD;
&#xD;
          -  Patients must not have any evidence of bleeding diathesis or coagulopathy&#xD;
&#xD;
          -  Patients with PT INR &gt; 1.5 are excluded, unless the patient is on full dose warfarin&#xD;
&#xD;
          -  Patients on full-dose anticoagulants (e.g., warfarin) are eligible provided that both&#xD;
             of the following criteria are met:&#xD;
&#xD;
               -  The patient has an in-range INR (usually between 2 and 3) on a stable dose of&#xD;
                  oral anticoagulant or on a stable dose of low molecular weight heparin&#xD;
&#xD;
               -  The patient has no active bleeding or pathological condition that carries a high&#xD;
                  risk of bleeding (e.g., tumor involving major vessels or known varices)&#xD;
&#xD;
               -  NOTE: Patients on a full dose of anticoagulants will a different schedule for&#xD;
                  PT/INR evaluations&#xD;
&#xD;
          -  Prophylactic anticoagulation (i.e. low dose warfarin) are eligible provided their&#xD;
             coagulation parameter levels are as follows: prothrombin time (INR; International&#xD;
             Normalized Ratio of prothrombin time) &lt; 1.1 x institutional upper limit of normal&#xD;
&#xD;
          -  Patients with known abnormalities of the cornea based on history (e.g., dry eye&#xD;
             syndrome, Sjogren's syndrome), congenital abnormality (e.g., Fuch's dystrophy),&#xD;
             abnormal slit-lamp examination using a vital dye (e.g., fluorescein, Bengal Rose),&#xD;
             and/or an abnormal corneal sensitivity test (Schirmer test or similar tear production&#xD;
             test) are excluded&#xD;
&#xD;
          -  Patients with any condition (e.g., gastrointestinal tract disease resulting in an&#xD;
             inability to take oral medication or a requirement for IV alimentation, prior surgical&#xD;
             procedures affecting absorption, or active peptic ulcer disease) that impairs their&#xD;
             ability to swallow pills are excluded&#xD;
&#xD;
          -  Patients cannot be receiving cytochrome P450-inducing anticonvulsants (EIAEDs; e.g.,&#xD;
             phenytoin, carbamazepine, phenobarbital, primidone, oxcarbazepine) and must not have&#xD;
             taken them for at least 10 days&#xD;
&#xD;
          -  Patients may not have allergies to or a history of allergic reactions attributed to&#xD;
             erlotinib and/or sorafenib&#xD;
&#xD;
          -  Eligibility of patients receiving any other medications or substances known to affect&#xD;
             or with the potential to affect the activity or pharmacokinetics of erlotinib or&#xD;
             sorafenib will be determined following review of their case by the Principal&#xD;
             Investigator&#xD;
&#xD;
          -  HIV patients receiving combination anti-retroviral therapy will be excluded&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Peereboom, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New Approaches to Brain Tumor Therapy Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Peereboom DM, Ahluwalia MS, Ye X, Supko JG, Hilderbrand SL, Phuphanich S, Nabors LB, Rosenfeld MR, Mikkelsen T, Grossman SA; New Approaches to Brain Tumor Therapy Consortium. NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme. Neuro Oncol. 2013 Apr;15(4):490-6. doi: 10.1093/neuonc/nos322. Epub 2013 Jan 17.</citation>
    <PMID>23328813</PMID>
  </results_reference>
  <verification_date>March 2016</verification_date>
  <study_first_submitted>March 7, 2007</study_first_submitted>
  <study_first_submitted_qc>March 7, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2007</study_first_posted>
  <results_first_submitted>March 25, 2016</results_first_submitted>
  <results_first_submitted_qc>March 25, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 27, 2016</results_first_posted>
  <last_update_submitted>March 25, 2016</last_update_submitted>
  <last_update_submitted_qc>March 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Gliosarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Adult pts accured in an outpatient clinic between Jan 2007 and October 2007.&#xD;
pts had to have measurable , histologically proven GBM, that had progressed following radiation therapy and 0-2 prior chemotherapies.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment</title>
          <description>Patients receive oral erlotinib hydrochloride 150 mg once daily and oral sorafenib tosylate 400 mg twice daily on days 1-28. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.&#xD;
Other: pharmacological study&#xD;
erlotinib hydrochloride 150mg: Given orally once daily&#xD;
sorafenib tosylate 400mg: Given orally twice daily&#xD;
pharmacological study: Correlative studies</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>histologically confirmed GBM, progressed or recurred following RT and 0-2 prior chemotherapy regimens</population>
      <group_list>
        <group group_id="B1">
          <title>Treatment</title>
          <description>Patients receive oral erlotinib hydrochloride 150mg once daily and oral sorafenib tosylate 400mg twice daily on days 1-28. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.&#xD;
Other: pharmacological study&#xD;
erlotinib hydrochloride: 150mg Given orally once daily&#xD;
sorafenib tosylate: 400mg Given orally twice daily&#xD;
pharmacological study: Correlative studies</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="56"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56" lower_limit="31" upper_limit="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Karnosky Performance Status</title>
          <description>100 - Normal; no complaints; no evidence of disease 90 - Able to carry on normal activity; minor signs or symptoms of disease 80 - Normal activity with effort; some signs or symptoms of disease 70 - Cares for self; unable to carry on normal activity or to do active work 60 - Requires occasional assistance, but is able to care for most of his personal needs</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>90-100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60-80</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival</title>
        <description>death. measured by time of first day of treatment until date of death, assessed up to 2 years.</description>
        <time_frame>Time of first day of the treatment to death, assessed up to 2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Patients receive oral erlotinib hydrochloride 150mg once daily and oral sorafenib tosylate 400mg twice daily on days 1-28. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.&#xD;
Other: pharmacological study&#xD;
erlotinib hydrochloride 150mg: Given orally once daily&#xD;
sorafenib tosylate 400mg: Given orally twice daily&#xD;
pharmacological study: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>death. measured by time of first day of treatment until date of death, assessed up to 2 years.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" lower_limit="4.5" upper_limit="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>The overall failure rate will be estimated by dividing the number of events (death) with the total exposure time in the study cohort. 95% confidence intervals and median time of survival will be calculated using standard methods.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4</p_value>
            <p_value_desc>cox regression model was used to estimate the HR of death compared to NABTT historical control with same histology, adjusted for age, KPS, and surgical procedure</p_value_desc>
            <method>Regression, Cox</method>
            <method_desc>cox regression model used to estimate the HR of death compared to NABTT historical control same histology, adjusted for age, KPS, surgical procedure</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.6</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>6months -Progression-free Survival Rate</title>
        <description>defined patient started treatment is alive and progression free at the time of 26-week (6 months) follow-up</description>
        <time_frame>At 6 months- defined as patient started treatment is alive and progression free at the time of 26-week (6 months) follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Patients receive oral erlotinib hydrochloride 150mg once daily and oral sorafenib tosylate 400mg twice daily on days 1-28. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.&#xD;
Other: pharmacological study&#xD;
erlotinib hydrochloride: 150mg Given orally once daily&#xD;
sorafenib tosylate: 400mg Given orally twice daily&#xD;
pharmacological study: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>6months -Progression-free Survival Rate</title>
          <description>defined patient started treatment is alive and progression free at the time of 26-week (6 months) follow-up</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="8" upper_limit="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>events collected from first day of dosing till off treatment - approximately 2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment</title>
          <description>Patients receive oral erlotinib hydrochloride 150mg once daily and oral sorafenib tosylate 400mg twice daily on days 1-28. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.&#xD;
Other: pharmacological study&#xD;
erlotinib hydrochloride: 150mg Given orally once daily&#xD;
sorafenib tosylate: 400mg Given orally twice daily&#xD;
pharmacological study: Correlative studies</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>lipase increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>David Peereboom, MD</name_or_title>
      <organization>Adult Brain Tumor Consortium</organization>
      <phone>216-445-6068</phone>
      <email>peerebd@ccf.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

